Pharmacokinetics of iontophoretic sumatriptan administration
View Patent ↗Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
1. A method for treating a sumatriptan responsive state in a human in need thereof, comprising iontophoretically delivering to said human an effective amount of sumatriptan, or a salt thereof, using a current of 4 mA or greater during a first portion of a treatment period for about one hour without substantially irritating said human's skin, such that said sumatriptan responsive state in said human is treated.
2. The method of claim 1 , wherein an effective amount of the sumatriptan, or the salt thereof, delivered systemically is greater than 5 mg.
3. The method of claim 1 , wherein the sumatriptan, or salt thereof, is sumatriptan succinate.
4. The method of claim 1 , wherein the method further comprises iontophoretically administering to said human an effective amount of sumatriptan, or a salt thereof, using a current of 2 mA during a second portion of the treatment period.
5. The method of claim 4 , wherein the effective amount of sumatriptan, or salt thereof, delivered systemically to said human is greater than 5 mg.
6. The method of claim 5 , wherein the sumatriptan, or salt thereof, is sumatriptan succinate.
7. The method of claim 6 , wherein the sumatriptan responsive state is migraine.
8. An iontophoretic patch designed to iontophoretically deliver to a human sumatriptan, or a salt thereof, using a current of 4 mA or greater during a first treatment period for about one hour, without substantially irritating said human's skin.
9. The patch of claim 8 , wherein the patch systemically delivers greater than 5 mg of sumatriptan or salt thereof.
10. The patch of claim 8 , wherein the sumatriptan, or salt thereof, is sumatriptan succinate.
11. The patch of claim 8 , wherein the patch is further designed to iontophoretically deliver sumatriptan, or a salt thereof, using a current of 2 mA during a second treatment period.
12. The patch of claim 11 , wherein an amount of sumatriptan, or the salt thereof, delivered systemically to said human is greater than 5 mg.
13. The patch of claim 12 , wherein the sumatriptan, or salt thereof, is sumatriptan succinate.